Navigation Links
Breast cancer risk amplified by additional genes in combo with BRCA mutation
Date:4/16/2008

PHILADELPHIA - Many women with a faulty breast cancer gene could be at greater risk of the disease due to extra risk-amplifying genes, according to research published this month in the American Journal of Human Genetics.

Researchers at the University of Pennsylvania School of Medicine join an international consortium of research groups that looked at more than 10,000 women carrying a BRCA1 or BRCA2 mutation for breast-cancer risk.

These results suggest that knowledge of a BRCA1 or BRCA2 mutation is necessary, but not sufficient, to fully understand cancer risk in women who carry these mutations, says co-author and head of the North American coalition Timothy R. Rebbeck, PhD, Professor of Epidemiology at Penn. This paper demonstrated that other genes, and possibly exposures, could provide important information that may refine our ability to predict cancer in this high-risk population. Because carriers of BRCA1 or BRCA2 mutations are relatively rare in the population, the only way to undertake studies of this type is by forming large consortia. Rebbeck is also the Associate Director for Population Science at Penns Abramson Cancer Center.

This is the first time we have found evidence that common changes in other genes can amplify the risk of breast cancer in women known to have faulty BRCA genes, says lead author Professor Doug Easton, director of Cancer Research UKs Genetic Epidemiology Unit at the University of Cambridge. This is the first step in finding a set of genes that modify the risk in BRCA carriers, and may influence how we monitor women with a family history of the disease.

The international team of scientists have found that common versions of two genes FGFR2 and TNRC9 known to increase breast cancer risk in the general population also increase the risk in women carrying damaged versions of the BRCA2 gene.

Around one in eighteen women will develop breast cancer by the age of 65. On average, half of women carrying a faulty BRCA2 gene will develop the disease by the age of 70.

This study found that particular combinations of the FGFR2 and TNRC9 genes modify breast cancer risk in BRCA2 mutation carriers. One percent of BRCA2 mutation carriers have the highest risk combination of FGFR2 and TNRC9 genes. Seven in every 10 women in this category are predicted to develop breast cancer.

Around twenty percent of the BRCA2 mutation carriers have the lowest risk combination of the FGFR2 and TNRC9 genes. The researchers found that their risk is lowered so four in every 10 women in this category are expected to develop the disease.

These findings are the first step in a series of studies hunting for breast cancer susceptibility genes, which aims to better monitor and treat women with a family history of the disease.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Research collaboration seeks blood test for aggressive breast cancer
2. MRI before surgery leads to better-adapted treatment for breast cancer
3. Obese women disadvantaged in both breast cancer treatment and diagnosis
4. Hereditary breast cancer -- a high cost to patient and health care provider alike
5. Tracking and feedback registry helps reduce disparities in breast cancer care
6. Breast Cancer Unchanged in Black Women, Despite Drop in HRT Use
7. Study finds media coverage of breast cancer focuses too little on prevention
8. Detecting, Diagnosing Breast Cancers
9. NovoCure presents results from breast cancer pilot study
10. OHSU Cancer Institute researchers find connection between protein, prognosis in breast cancer
11. Drinking May Raise Breast Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... AvePoint ... seventh North American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 ... attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether ... teacher quality, the field must first improve teacher preparation program design. It then ... next” and that decades of input- and outcome-based research has failed to improve ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as it ... either don’t have access to a health care facility or a pharmacy within 60 minutes ... the United States or for many who are faced with health or personal issues that ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, ... real estate valuation industry for more than 40 years. , “Ruel is a ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... state legislatures and Congress to protect parental rights and civil liberties, and to ... in America. , The demonstration coincides with a press conference taking place Friday ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)... 28, 2017  "US Cancer Generics Market Outlook ... indicators and trend analysis related to the emergence ... pharmaceutical market in US. The report analyzes various ... on cancer generics drugs in recent years. The ... billions of dollars for various stake holders involved ...
(Date:3/28/2017)... Therapeutics, Inc. (Nasdaq: OREX ) today announced ... year ended December 31, 2016. "Last ... beginning with the re-acquisition of the rights to Contrave® ... at Orexigen demonstrated remarkable focus, executing on a myriad ... Company while rewarding us full control of our FDA ...
Breaking Medicine Technology: